M Screening checklist for biotherapeutic products and their corresponding SBPs - Abridged Pathway DOCX
M Section guidance for part 3 — patient information leaflet (PIL) — of a WHO Public Assessment Report (WHOPAR) (24 October 2016) PDF
M Section guidance for part 4 — summary of product characteristics (SmPC) — of a WHO Public Assessment Report (WHOPAR) (25 October 2016) PDF
M Section guidance for part 5 — labelling — of a WHO Public Assessment Report (WHOPAR) (24 October 2016) PDF
M Section guidance for part 6 of — scientific discussion — of a WHO Public Assessment Report (WHOPAR) (25 October 2016) PDF
M Stability data for finished pharmaceutical products (FPPs) approved by stringent regulatory authorities (SRAs) PDF
M Stability testing of active pharmaceutical ingredients and finished pharmaceutical products - TRS 1010 - Annex 10 PDF
M Stability testing of active pharmaceutical ingredients and finished pharmaceutical products - WHO Technical Report Series, No.1010, Annex 10, 2018 PDF
M Stringent regulatory authority sharing of non-public information concerning product with the national regulatory authority and the World Health Organization (WHO), Annex 3A DOCX
M Survey of the quality of anti-tuberculosis medicines circulating in selected newly independent states of the former Soviet Union (issued November 2011) PDF
M Survey of the quality of antiretroviral medicines circulating in selected African countries (issued September 2007) PDF
M Survey of the quality of medicines identified by the United Nations Commission on Life Saving Commodities for women and children PDF
M Survey of the quality of selected antimalarial medicines circulating in six countries of sub-Saharan Africa (issued January 2011) PDF
M Survey of the quality of selected antiretroviral medicines circulating in five African countries (2019) PDF